Heart Rhythm 2025: 4 Key PFA Studies Shaping AFib Treatment

Pulsed Field Ablation (PFA) is rapidly becoming the gold standard for atrial fibrillation (AFib) treatment, and new data from Heart Rhythm 2025 in San Diego confirms its growing dominance. With Boston Scientific, Medtronic, Abbott, and Johnson & Johnson all unveiling pivotal trial results, this article breaks down the 4 most impactful PFA studies—revealing safety, efficacy, and what’s next for AFib care.

How Did Boston Scientific’s Farapulse Perform in Persistent AFib?

Boston Scientific’s Farapulse showcased a 73.4% efficacy rate in treating persistent AFib, marking a significant milestone in PFA technology.

Abbott’s Volt PFA: What Do the 1-Year Results Show?

Abbott’s Volt PFA demonstrated promising 1-year results, with a notable reduction in procedure time and improved patient outcomes.

Is Medtronic’s Sphere-360 the Future of Single-Shot PFA?

Medtronic’s Sphere-360 introduces a revolutionary single-shot PFA approach, potentially setting a new standard for AFib treatment efficiency.

J&J’s Omnypulse: Early Success in Paroxysmal AFib?

Johnson & Johnson’s Omnypulse reported early success in treating paroxysmal AFib, highlighting the versatility and effectiveness of PFA technology.

Conclusion

The PFA revolution is here, with Heart Rhythm 2025 solidifying its role in AFib care. From Boston Scientific’s Farapulse to J&J’s Omnypulse, these studies highlight safer, faster, and more effective treatments. Stay ahead—Explore the latest PFA advancements or Subscribe for updates on AFib innovations.